- Home
- CHRO vs SONN Comparison
CHRO vs SONN Comparison
Compare CHRO & SONN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRO
- SONN
- Stock Information
- Founded
- CHRO 2002
- SONN N/A
- Country
- CHRO United States
- SONN United States
- Employees
- CHRO N/A
- SONN N/A
- Industry
- CHRO
- SONN Biotechnology: Pharmaceutical Preparations
- Sector
- CHRO
- SONN Health Care
- Exchange
- CHRO Nasdaq
- SONN Nasdaq
- Market Cap
- CHRO 3.9M
- SONN 3.3M
- IPO Year
- CHRO 2024
- SONN N/A
- Fundamental
- Price
- CHRO $0.66
- SONN $3.02
- Analyst Decision
- CHRO Strong Buy
- SONN Strong Buy
- Analyst Count
- CHRO 1
- SONN 3
- Target Price
- CHRO N/A
- SONN $117.33
- AVG Volume (30 Days)
- CHRO 100.6K
- SONN 1.3M
- Earning Date
- CHRO 11-13-2024
- SONN 12-12-2024
- Dividend Yield
- CHRO N/A
- SONN N/A
- EPS Growth
- CHRO N/A
- SONN N/A
- EPS
- CHRO N/A
- SONN N/A
- Revenue
- CHRO N/A
- SONN $55,881.00
- Revenue This Year
- CHRO N/A
- SONN N/A
- Revenue Next Year
- CHRO N/A
- SONN N/A
- P/E Ratio
- CHRO N/A
- SONN N/A
- Revenue Growth
- CHRO N/A
- SONN N/A
- 52 Week Low
- CHRO $0.52
- SONN $2.85
- 52 Week High
- CHRO $6.00
- SONN $18.72
- Technical
- Relative Strength Index (RSI)
- CHRO 48.22
- SONN 25.74
- Support Level
- CHRO $0.63
- SONN $2.85
- Resistance Level
- CHRO $0.69
- SONN $10.02
- Average True Range (ATR)
- CHRO 0.06
- SONN 0.81
- MACD
- CHRO 0.01
- SONN -0.11
- Stochastic Oscillator
- CHRO 52.55
- SONN 2.37
About CHRO Chromocell Therapeutics Corporation
Chromocell Therapeutics Corp is a clinical-stage biotechnology company focused on developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain and other associated medical conditions. The company's initial clinical focus is to selectively target the sodium ion-channel known as NaV1.7 for the treatment of various types of chronic neuropathic pain and eye pain. The Company's portfolio also includes pre-clinical work on other sodium channel receptor subtypes, and the company intends to explore these and other compounds for the treatment of additional pain indications.
About SONN Sonnet BioTherapeutics Holdings Inc.
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.